ASBP Stock Heads For Best Week In Over 2 Months – Why This Drug Delivery Tech Firm Is Buying An Auto Supplier?

The company announced the acquisition of Dura Driver Control Systems for $30 million in cash.
Kraken Robotics on Tuesday announced that it has entered into an agreement to acquire Covelya Group Limited.(Image Courtesy: Getty Images)
Kraken Robotics on Tuesday announced that it has entered into an agreement to acquire Covelya Group Limited for $615 million.(Image Courtesy: Getty Images)
Profile Image
Arnab Paul·Stocktwits
Published Jun 12, 2026   |   10:14 AM EDT
Share
·
Add us onAdd us on Google
Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...Loading...
  • Aspire Biopharma said it is looking to diversify its revenue streams and boost its earnings and cash flow profile.
  • Dura Driver Control Systems is a global automotive supplier with an annual revenue of $200 million.
  • It operates 11 manufacturing facilities across North America, Europe, and Asia and holds more than 310 patents.

Advertisement|Remove ads.

Shares of Aspire Biopharma Holdings (ASBP) drew investor attention on Friday after the company announced an expansion into the automotive sector through the acquisition of Dura Driver Control Systems.

ASBP stock is heading for its best week in more than two months.

Read Next
Loading...
Loading...

Why Is ASBP Acquiring DCS?

Aspire Biopharma, a firm with patent-pending drug-delivery technology, said it is looking to diversify its revenue streams and boost its earnings and cash flow profile. According to its latest earnings report for the year ended Dec. 31, 2025, Aspire, a pre-revenue company, posted a loss of more than $24 million.

Advertisement|Remove ads.

Dura Driver Control Systems (DCS), a global automotive supplier of electronic driver control systems for electric vehicles, generates more than $200 million in annual revenue. DCS operates 11 manufacturing facilities across North America, Europe, and Asia and holds more than 310 patents.

“Concurrently, this strengthened financial foundation allows us to optimize our proprietary drug delivery technology and advance commercial opportunities for our innovative caffeine product portfolio,” said Kraig Higginson, Interim CEO and Chairperson of the Aspire Biopharma Board.

How Did ASBP Fund The Acquisition?

Aspire will acquire 100% of DCS for $30 million in cash, with the transaction expected to close in the third quarter of 2026.

Advertisement|Remove ads.

In April, the company secured a commitment for a senior secured credit facility of up to $22.5 million to help fund its acquisition. The five-year loan is expected to cover a significant portion of the purchase price. On Monday, the company said it does not plan to raise new equity to complete the deal.

Retail Bullish Despite Early Decline

Retail sentiment on Stocktwits for ASBP turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘high’ message volumes.

On May 11, the company implemented a one-for-thirty reverse share split.

Advertisement|Remove ads.

Read also: GMM Stock Soared 60% Pre-Market Today – A Look At Some Key Highlights That Got Investors Talking


For updates and corrections, email newsroom[at]stocktwits[dot]com.

Comments
Share your thoughts...

Comments posted here will also appear on symbol pages.

Follow on Google News
Read about our editorial guidelines and ethics policy

Advertisement|Remove ads.